Modulation of Somatic Repeat Expansion as a Therapeutic Approach to Huntington's Disease

调节体细胞重复扩增作为亨廷顿病的治疗方法

基本信息

项目摘要

PROJECT SUMMARY Huntington’s disease (HD) is caused by expanded trinucleotide repeats (CAG) in exon 1 of the huntingtin (HTT) gene. Therapies lowering the downstream mutant HTT protein show limited clinical success. New evidence reveals that repeat tract length in the HTT locus, not mutant HTT protein, correlates to disease onset/severity. CAG repeat length is inherited, but further expands due to somatic instability, which contributes to HD progression. Modulating somatic expansion is a key path toward treating HD. Somatic expansion occurs in non- dividing cells like neurons when DNA repeats misalign after transcription, forming a slipped loop that activates mismatch repair (MMR). In MMR, nuclease complexes help recognize the slipped loop and cut the non-slipped strand to create a gap that is filled to expand the repeat. Polymorphisms in MMR complexes are linked to HD onset, and knocking out or altering activity of MMR proteins block expansion or induce contraction in HD models. Yet, the contribution of each MMR protein to CAG expansion, and the effect of their conditional CNS-specific reduction on HD outcomes, is untested. Also, mechanisms favoring contraction over expansion are unknown. This project seeks to define MMR complexes facilitating HTT CAG expansion/contraction using divalent small interfering RNA (siRNA)—which induce potent, CNS-specific silencing of target genes—and antisense oligonucleotides (ASOs)—which can disrupt specific protein-nucleic acid binding in the CNS. Aim 1 will use divalent siRNA to evaluate the effects of MMR silencing on HTT CAG repeat expansion and HD progression. Efficacies of siRNAs targeting each MMR protein have been validated in human and mouse cells. Furthermore, one of these siRNAs was delivered to CNS of an HD mouse model, BAC-CAG (carries human HTT with 120 CAG that undergo expansion), showing target MMR silencing and blocked somatic expansion 2 months later. In Aim 1, divalent siRNA targeting each MMR enzyme will be injected into BAC-CAG mice. Target silencing and HTT CAG repeat expansion will be measured 2 months later. Top siRNA that block expansion will be re- injected into BAC-CAG mice, and the impact on motor behavior, ventricular size, and HD pathology will be explored over 9 months. Aim 2 will develop HTT CAG-targeting ASOs to induce MMR-mediated contraction in HD cells and mice. An initial panel of ASOs targeting HTT CAG repeats was screened in non-transformed HD patient-derived fibroblasts (HDpFs) using a high-throughput format, and ASOs that increase contraction events were identified. To improve contraction rates, ASO chemistries and lengths will be optimized and screened in HDpFs using the same assay. HTT CAG repeat length/instability will be quantified over 40 days to identify leads. Leads will be delivered to HDpFs, in combination with validated siRNA targeting each MMR protein, to identify MMR proteins mediating ASO-induced contraction events. In parallel, in vivo efficacy of leads will be confirmed in BAC-CAG mice. This work will reveal somatic expansion/contraction mechanisms, inform HD therapy design, and provide the fellow with crucial training in therapeutic development, neurobiology, and bioinformatics.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jillian Belgrad其他文献

Jillian Belgrad的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Development of Antisense Oligonucleotides to Regulate Gamma' Fibrinogen Levels
开发反义寡核苷酸来调节γ纤维蛋白原水平
  • 批准号:
    10759950
  • 财政年份:
    2023
  • 资助金额:
    $ 3.25万
  • 项目类别:
Inducing H3F3A exon skipping with antisense oligonucleotides as an approach to treat diffuse intrinsic pontine glioma
用反义寡核苷酸诱导 H3F3A 外显子跳跃作为治疗弥漫性内源性脑桥胶质瘤的方法
  • 批准号:
    10677284
  • 财政年份:
    2023
  • 资助金额:
    $ 3.25万
  • 项目类别:
Inducing PKM splice-switching with antisense oligonucleotides as an approach to treat hepatocellular carcinoma
用反义寡核苷酸诱导 PKM 剪接转换作为治疗肝细胞癌的方法
  • 批准号:
    10464020
  • 财政年份:
    2022
  • 资助金额:
    $ 3.25万
  • 项目类别:
Promoting adult hippocampal neurogenesis using antisense oligonucleotides as an Alzheimer's disease therapy
使用反义寡核苷酸促进成人海马神经发生作为阿尔茨海默氏病的治疗
  • 批准号:
    10484703
  • 财政年份:
    2022
  • 资助金额:
    $ 3.25万
  • 项目类别:
Strategy for specific delivery of antisense oligonucleotides to T cells
将反义寡核苷酸特异性递送至 T 细胞的策略
  • 批准号:
    10547347
  • 财政年份:
    2022
  • 资助金额:
    $ 3.25万
  • 项目类别:
Metabolism of Antisense Oligonucleotides and other Polyanions in Liver
反义寡核苷酸和其他聚阴离子在肝脏中的代谢
  • 批准号:
    10806783
  • 财政年份:
    2022
  • 资助金额:
    $ 3.25万
  • 项目类别:
Metabolism of Antisense Oligonucleotides and other Polyanions in Liver
反义寡核苷酸和其他聚阴离子在肝脏中的代谢
  • 批准号:
    10689248
  • 财政年份:
    2022
  • 资助金额:
    $ 3.25万
  • 项目类别:
Metabolism of Antisense Oligonucleotides and other Polyanions in Liver
反义寡核苷酸和其他聚阴离子在肝脏中的代谢
  • 批准号:
    10501862
  • 财政年份:
    2022
  • 资助金额:
    $ 3.25万
  • 项目类别:
Inducing PKM splice-switching with antisense oligonucleotides as an approach to treat hepatocellular carcinoma
用反义寡核苷酸诱导 PKM 剪接转换作为治疗肝细胞癌的方法
  • 批准号:
    10623180
  • 财政年份:
    2022
  • 资助金额:
    $ 3.25万
  • 项目类别:
Identifying binding partners, biological substrates and antisense oligonucleotides regulating expression of short and long ACE2.
识别调节短和长 ACE2 表达的结合伴侣、生物底物和反义寡核苷酸。
  • 批准号:
    BB/V019848/1
  • 财政年份:
    2021
  • 资助金额:
    $ 3.25万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了